Executive summary

This study compared the results of 31 patients with locally advanced esophageal cancer treated with neoadjuvant chemoradiotherapy to a median total dose 41.4 Gy using either proton (n = 15) or photon (n = 16). With a median follow-up of 17 months, this study reported no significant differences between the two groups in 2-year OS (67.8% vs. 68.6%, p = 0.867) or 2-year DFS (33.3% vs. 34.5%, p = 0.749). The lungs and heart received significantly less dose in the proton group, however there was no significant differences in short-term postoperative outcomes or lymphocyte count. 

Key content topics
Top cancer treatments